Compare Abeona Therapeutics Inc (ABEO) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Oklo Inc — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while Oklo Inc trades at $46.29 (market cap $8.74B). The key difference: Oklo Inc is far larger — about 20.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | OKLO | |
|---|---|---|
Market Cap | $421.19M | $8.74B |
Sector | Health | Technology |
52-Week High | $7.45 | $174.14 |
52-Week Low | $4.17 | $36.84 |
Enterprise Value | $276.10M | $6.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OKLO trades at $46.41, up 4.32% over 24 hours, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $77.07. The company reported its first revenue of $1.2 million in Q2 2026 but continues to post significant losses, with a net income margin of -12,625.54% in 2026. Recent milestones include achieving first criticality at its Groves isotope reactor, though cash burn remains high as it advances Aurora nuclear projects.
Outlook is speculative with high growth potential in nuclear energy infrastructure, but risks include persistent losses, execution challenges, and reliance on financing. Analyst sentiment is strongly bullish (76.9% buy ratings), yet investors must weigh the long-term payoff against near-term financial instability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
